Invivyd (IVVD) Stock Analysis: AI Score & Alternative Data
IVVD alt-data: headcount climbing, job postings lagging
Is Invivyd a buy right now? The alternative data says hold. This IVVD stock analysis is built on the 25+ alternative data signals AltIndex tracks on Invivyd every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 40/100: a Hold. The stock trades at $0.69 with a $198M market cap.
The bullish side of the 90-day ledger: headcount (according to LinkedIn) up 30.3% to 189 employees, and Reddit mentions up 200.0% to 3 a day. The drag: job postings down 61.1% to 14 open roles, web traffic down 60.7% to 11K monthly visits, and just 17% of employees report a positive business outlook. That tension is what keeps the score mid-range.
IVVD’s broader alt-data profile also covers X followers (3K), and sentiment (92/100). Every signal links to its own page with full history, the IVVD technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on IVVD is just below.
Invivyd AI Stock Analysis
Invivyd is a biotechnology company focused on developing cutting-edge treatments and therapies. Known for its innovative approach in the field of antibodies and immunology, Invivyd has garnered attention for its research and development initiatives.
Analysis generated August 2, 2026.
Recent Invivyd Stock Alerts
|
Invivyd | August 10 Price is down by -6% in the last 24h. |
|
Invivyd | August 7 Price is up by 6.7% in the last 24h. |
|
Invivyd | August 6 Price is up by 7.5% in the last 24h. |
|
Invivyd | August 5 Price is up by 6% in the last 24h. |
Invivyd Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 11K | 60.7% | |
| Job Posts | 14 | 61.1% | |
| LinkedIn Employees | 189 | 30.3% | |
| Employee Recommend | 32 | 0% | |
| Business Outlook | 17 | 0% | |
| Sentiment | 92 | 8.0% | |
| Reddit Mentions | 3 | 200.0% | |
| X Mentions | 1 | 96.8% | |
| Stocktwits Mentions | 29 | 6.5% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 6K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 3K | 1.9% |
About Invivyd (IVVD)
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
| Price | $0.69 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $198M |
| Year Range | $1 – $3 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Invivyd News
View more →
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4 - GlobeNewswire |
|
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDAJuly 6 - GlobeNewswire |
|
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2 - GlobeNewswire |
|
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 VaccineJune 16 - GlobeNewswire |
|
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-AdministrationJune 9 - GlobeNewswire |
Invivyd Earnings & Financial Performance
View all earnings →Invivyd Insider Trading Activity
View all →| Andersen Jill filed to sell 181,736 shares at $0.0. Feb 18 '26 |
| Lee Timothy Edward filed to sell 117,717 shares at $0.0. Feb 18 '26 |
| Duke William E. filed to sell 107,717 shares at $0.0. Feb 18 '26 |
| Green Julie filed to sell 107,717 shares at $0.0. Feb 18 '26 |
| Allen Robert D. III filed to sell 114,487 shares at $0.0. Feb 18 '26 |
Invivyd Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Invivyd
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Korro BioKRRO |
$13.32 1.3% | $199M | 41 |
 |
Tonix PharmaceuticalsTNXP |
$12.34 2.0% | $201M | 53 |
 |
Voyager TherapeuticsVYGR |
$3.20 1.0% | $201M | 38 |
 |
HumacyteHUMA |
$0.71 4.6% | $194M | 52 |
 |
Alpha CognitionACOG |
$8.89 0.1% | $194M | 54 |
Explore Invivyd Data
Frequently Asked Questions: Invivyd (IVVD)
Invivyd has an AltIndex AI Score of 40/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
40/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Invivyd (IVVD) stock is $0.69 with a market cap of $198M.
As of today, Invivyd’s PE (Price to Earnings) ratio is —.
View the latest Invivyd insider transactions to see recent buying and selling activity by company executives and directors.
Check the Invivyd congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The IVVD stock price chart above shows Invivyd’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Invivyd technical analysis for RSI, moving averages, and more.
See the stocks similar to Invivyd section on this page for companies in the same industry ranked by market cap and AI Score.
